Real‐world data on prognostic value of measurable residual disease assessment by fragment analysis or next‐generation sequencing in multiple myeloma

Summary Measurable residual disease (MRD) negativity is a strong prognostic indicator in multiple myeloma (MM). However, the optimal use of MRD in daily clinical practice has been hampered by the limited feasibility of MRD testing. Therefore, we examined the clinical relevance of commercially available MRD modalities based on clonality assays by fragment analysis with IdentiClone® ( n = 73 patients) and next‐generation sequencing (NGS) with LymphoTrack® ( n = 116 patients) in newly diagnosed patients with MM who received autologous stem cell transplantation (ASCT). MRD was assessed at the end of induction (pre‐ASCT) and/or at 100 days after ASCT (post‐ASCT). MRD could not predict survival when assessed by fragment analysis. However, NGS‐based MRD negativity at pre‐ or post‐ASCT was beneficial in terms of progression‐free and overall survival. Moreover, NGS‐based MRD negativity was independently associated with improved progression‐free and overall survival, and MRD‐positive patients both pre‐ and post‐ASCT had worst outcome. Indeed, initial adverse prognostic features by high‐risk cytogenetics could be mitigated upon achieving MRD negativity by NGS. We demonstrate the feasibility and clinical benefit of achieving MRD negativity by commercially available clonality‐based MRD assays in MM and support incorporating NGS, but not fragment analysis, to tailor therapeutic strategies in real‐world practice.